Arcturus Therapeutics provides update on OTC deficiency and CF programmes
Betsy Goodfellow | July 2, 2024 | News story | Research and Development | Arcturus Therapeutics, OTC, Pharmacy, clinical trials, cystic fibrosis
Arcturus Therapeutics has announced mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, an investigational inhaled mRNA therapeutic for the treatment of cystic fibrosis (CF).
The update surrounding ARCT-810 for OTC deficiency surrounded the completion of enrollment into a double-blind phase 2 study for adolescents and adults at a 0.3mg/kg dose level. The patients will be randomised at a ratio of 3:1 and will be given six doses of the drug or placebo every 14 days. Treatment and follow-up are expected later this year, with full safety and biomarker data.
As for ARCT-032 for CF treatment, the company is intending to submit an investigational new drug (IND) application for a phase 2 multiple ascending dose study within the next 60 days. This study is expected to identify a safe and effective dose in Class 1 (null) and other CF patients who do not benefit from CFTR modulators.
Dr Juergen Froehlich, chief medical officer at Arcturus Therapeutics, commented: “CFTR replacement using mRNA therapeutics is an area of significant medical interest, as it may benefit null patients and potentially many other CF patients. The safety profile of ARCT-032 observed in phase 1 and after two administrations in phase 1b for patients dosed to date, including the trend of lung function improvement in the Class I participant, is encouraging. These data are supportive of expanding our clinical program to the US and other regions with a phase 2 multiple ascending dose protocol, and I look forward to a successful conduct and outcome of this planned study. We are also excited to have started patient screening for the expansion of our ARCT-810 clinical programme in the US to more severely affected OTC deficiency patients.”
Betsy Goodfellow
Related Content
EMA selects TrialAssure anonymisation platform for clinical trial documents
TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency …
Vesper Bio reports positive topline results for dementia candidate
Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has …
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
